Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Ann Parasitol ; 63(3): 173­181, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29274210

RESUMO

Cerebral toxoplasmosis is caused by the protozoan Toxoplasma gondii because of reactivation of latent tissue cysts in the Acquired Immunodeficiency Syndrome (AIDS) patients with severe immunosuppression. The objective of this study was to evaluate the benefit of co-trimoxazole in presumptive and prevention of cerebral toxoplasmosis in Human Immunodeficiency Virus (HIV)/AIDS patients at Bobo-Dioulasso Hospital in Burkina Faso from June 2012 to October 2014. ELISA and ELFA were performed on serum for the quantitative determination of IgG and IgM anti-T. gondii, respectively. The seroprevalence of toxoplasmosis was 29.3%. No IgM antibodies for T. gondii were found. Six patients with Toxoplasma-specific antibodies presented cerebral toxoplasmosis. All patients were infected by HIV-1 with the median of CD4+ T lymphocytes at 141 cells/µl. No patient was under antiretroviral therapy. No case of cerebral toxoplasmosis was noted in patients receiving co-trimoxazole in prevention. Presumptive treatment of cerebral toxoplasmosis with co-trimoxazole was effective in all patients with a significant clinical improvement in 83.3%. These results attest the benefit of cotrimoxazole in cerebral toxoplasmosis treatment in countries where drug resources are limited when sulfadiazine is not available. Ours finding highlight the importance of establishing toxoplasmosis chemoprophylaxis to HIV with severe immunosuppression patients and positive Toxoplasma serology.


Assuntos
Infecções por HIV/complicações , Toxoplasmose Cerebral/complicações , Toxoplasmose Cerebral/tratamento farmacológico , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Adulto , Antibacterianos/economia , Antibacterianos/uso terapêutico , Burkina Faso/epidemiologia , Estudos Transversais , Feminino , Infecções por HIV/epidemiologia , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Masculino , Pessoa de Meia-Idade , Fatores Socioeconômicos , Toxoplasmose Cerebral/sangue , Toxoplasmose Cerebral/epidemiologia , Combinação Trimetoprima e Sulfametoxazol/economia , Adulto Jovem
2.
Med Mal Infect ; 35(7-8): 383-9, 2005.
Artigo em Francês | MEDLINE | ID: mdl-15975752

RESUMO

OBJECTIVES: This retrospective study was carried out to determine the prevalence of cerebromeningeal diseases at the Fann Teaching Hospital Infectious Diseases Clinic, in Dakar, and to describe their epidemiological, clinical, and etiological features. PATIENTS AND METHODS: Data was collected for analysis from patients files recorded from January 1, 2001 to December 31, 2003. RESULTS: Four hundred seventy cases were identified (11.4% of total admissions) with a M/F sex ratio of 1.38 and a mean age of 33 years. Eighty-nine patients were infected by HIV and clinical presentations included fever (78%), meningeal syndrome (57.4%), coma (64.9%), convulsions (19%), focal neurological deficits (15.5%), and cranial nerves dysfunction (7.2%). Etiologies presented as cerebral malaria (85 cases), purulent meningitis (51 cases), neuromeningeal cryptococcosis (37 cases), tuberculous meningitis (11 cases), intracranial abscess (10 cases), toxoplasma encephalitis (4 cases), cerebrovascular attack (11 cases), and cerebromeningeal hemorrhages (3 cases). In as many as 248 cases (52.8%) no etiology could be found. The case fatality rate was 44.5% overall (209 deaths) and 68.5% among HIV-infected patients. Neurological sequels were found in 22 survivors (8.8%), consisting in focal neurological deficit (12 cases), deafness (5 cases), diplopia (2 cases), dementia (2 cases), postmeningitic encephalitis (1 case). CONCLUSION: These results show the need to improve our technical capacities in our diagnostic laboratories, the prevention of opportunistic infections in the course of HIV/AIDS infection, and the involvement of various specialists in the management of cerebromeningeal diseases.


Assuntos
Encefalopatias/epidemiologia , Meningite/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Hemorragia Cerebral/epidemiologia , Criança , Pré-Escolar , Coma/epidemiologia , Grupos Diagnósticos Relacionados , Encefalite/epidemiologia , Feminino , Infecções por HIV/epidemiologia , Mortalidade Hospitalar , Hospitais Universitários/estatística & dados numéricos , Humanos , Malária Cerebral/epidemiologia , Masculino , Meningite Criptocócica/epidemiologia , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Estações do Ano , Senegal/epidemiologia , Acidente Vascular Cerebral/epidemiologia , Toxoplasmose Cerebral/epidemiologia , Tuberculose do Sistema Nervoso Central/epidemiologia
3.
Expert Rev Mol Diagn ; 2(6): 616-24, 2002 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-12465457

RESUMO

Toxoplasma gondii is a ubiquitous pathogen that causes significant morbidity and mortality in immunocompromised patients. Although relatively uncommon, toxoplasmosis is increasingly recognized as a severe complication of hematopoietic stem cell transplantation. Timely and accurate diagnosis of this treatable infection is critical. PCR-based testing has become the preferred method for diagnosis, occasionally replacing tissue biopsy. This article reviews the clinical, diagnostic and therapeutic aspects of toxoplasmosis in the setting of hematopoietic stem cell transplantation and the current and future role of PCR-based testing for early detection and diagnosis.


Assuntos
Transplante de Células-Tronco de Sangue Periférico , Reação em Cadeia da Polimerase/métodos , Toxoplasmose/diagnóstico , Animais , Anticorpos Antiprotozoários/sangue , Anticorpos Antiprotozoários/imunologia , Antiprotozoários/uso terapêutico , Sistemas Computacionais , DNA de Protozoário/análise , Previsões , Humanos , Hospedeiro Imunocomprometido , Programas de Rastreamento/economia , Pré-Medicação , Sensibilidade e Especificidade , Estudos Soroepidemiológicos , Toxoplasma/genética , Toxoplasma/imunologia , Toxoplasmose/economia , Toxoplasmose/epidemiologia , Toxoplasmose/prevenção & controle , Toxoplasmose Cerebral/diagnóstico , Toxoplasmose Cerebral/epidemiologia , Toxoplasmose Cerebral/prevenção & controle , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA